Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
Go back to Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 232.97 -3.25 (1.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $236.22 | 52 Week High | $109.10 | |||
| Open | $235.83 | 52 Week Low | $31.38 | |||
| Day High | $236.80 | P/E | N/A | |||
| Day Low | $228.59 | EPS | $-1.45 | |||
| Volume | 896,251 | |||||
